Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/707511/000114420419012259/tv515505_8k.htm
November 2021
July 2021
July 2021
May 2021
March 2021
October 2020
October 2020
September 2019
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/707511/000114420419012259/tv515505_8k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Regenerx Biopharmaceuticals Inc.
Regenerx Biopharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Regenerx Biopharmaceuticals Inc provided additional information to their SEC Filing as exhibits
Ticker: RGRXEvents:
CIK: 707511
Form Type: 8-K Corporate News
Accession Number: 0001144204-19-012259
Submitted to the SEC: Tue Mar 05 2019 4:53:26 PM EST
Accepted by the SEC: Tue Mar 05 2019
Period: Wednesday, February 27, 2019
Industry: Pharmaceutical Preparations